Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stopped early · Phase 2
Conditions studied: Urologic Neoplasms
In brief
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe the safety and tolerability at this dose and schedule
Key facts
- Study ID
- NCT00226954
- Run by
- Stanford University
- People needed
- 23
- Starts
- 2003-03-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2020-03-18
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.